Supporting the Detection of Early-Stage Disease with Use of Biomarkers
Kara Nyberg, PhDThe NELSON trial and the US National Lung Cancer Screening Trial (NLST) marked major advances in lung cancer by establishing that low-dose computed tomography (LDCT) screening of high-risk individuals is effective at catching the disease in early […] Read more
Leveraging ctDNA to Detect Minimal Residual Disease Following Surgery
Kara Nyberg, PhDCurative therapy remains elusive in early-stage NSCLC following surgical resection, sometimes even for patients with stage I disease. Adjuvant therapy can be of benefit, but only for a select few. As shown in the Lung Adjuvant […] Read more
ctDNA Offers a Window Into Emerging Mechanisms of Resistance to Targeted Therapy
Kara Nyberg, PhDTargeted therapy has undoubtedly transformed the treatment landscape for metastatic NSCLC, with multiple agents now available to target seven different molecular drivers. In tandem with the growing treatment armamentarium, comprehensive molecular profiling has been critical in providing insight […] Read more
Dr. Christian Rolfo Previews the New IASLC Consensus Statement on Liquid Biopsy
Joy CurzioIn his keynote address during the IASLC 2020 Hot Topic Meeting: Liquid Biopsy, co-chair Christian Rolfo, MD, PhD, MBA, provided an overview of the fastpaced evolution of liquid biopsy. In 2018, at the time of […] Read more
FDA Perspectives on the Use of Liquid Biopsy in NSCLC
Kara Nyberg, PhDThe US Food and Drug Administration (FDA) recognizes the value of liquid biopsy in managing patients with cancer, and the agency is actively working to bring these assays to the clinic. Harpreet Singh, MD, Director of […] Read more
Biopsy Options Create New Decision-making Points for Clinicians
Kara Nyberg, PhDUnderstanding the differences in liquid biopsy approaches, as well as how they complement tissue, can be important to therapeutic selection and outcomes. Read more
Como bien se sabe, el tabaquismo es una de las causas de cáncer y es responsable de 1 de cada 3 muertes por cáncer al año. Aunque se conocen los […] Read more
O uso de tabaco é um fator causador de câncer já comprovado, contribuindo com 1 em cada 3 mortes por câncer todos os anos. Embora os efeitos do tabagismo sejam […] Read more
喫煙は癌の原因として定着しており、年間約3人に1人の割合で癌死亡者が出ています。喫煙の有害な影響は十分に認識されていますが、癌と診断された後に喫煙を継続することの弊害は過少評価されています。癌患者や元癌患者が喫煙を続けると、全死亡率、癌関連死亡率、二次原発癌のリスクの増加を含む、治療転帰に悪影響を及ぼし、癌治療の毒性を著しく増大させます。癌と診断された後の喫煙の臨床効果は、癌治療費の増大にも大きく影響します。癌診断後に禁煙することで治療結果の改善が期待できますが、診断時に喫煙していた癌患者のほとんどは、治療中も喫煙を続けています。残念ながら、医療従事者が喫煙習慣のある患者と協力して禁煙を積極的に支援することはあまり多くありません。IASLC会... Read more
烟草的使用是一个明确的致癌原因,在癌症患者中,其每年的致死人数占总死亡人数的 1/3。虽然人们已经认识到了吸烟的危害,但在癌症诊断后继续吸烟的危害却没有得到应有的重视。癌症患者和幸存者继续吸烟会导致不良的治疗结果,包括增加总死亡率、癌症相关死亡率,以及出现第二原发癌的风险,并大大增加癌症治疗的毒副作用。同时,癌症诊断后吸烟的临床影响会对癌症治疗的费用产生巨大影响。癌症诊断后戒烟可以改善治疗结果,但大多数在诊断时有吸烟习惯的患者会在治疗期间仍保留这一习惯。遗憾的是,医疗服务提供者通常不会为其使用烟草的患者提供戒烟帮助来主动配合患者戒烟。我们在 IASLC 成员中展开的调查显示:大多数医疗专业人员已经认识到吸烟会导致不良的结果,其中 90% 的人... Read more